Keywords: CR; complete response; DEE; drug-eluting embolic; ÎPBV; change in median parenchymal blood volume; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PBV; parenchymal blood volume; PD; progressive disease; PR;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CI; confidence interval; CR; complete response; DEE; drug-eluting embolic; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PEG; polyethylene glycol; PR;
Keywords: DEE; drug-eluting embolic; FdUrd-C8; 3â²,5â²-dioctanoyl-5-fluoro-2â²-deoxyuridine; HCC; hepatocellular carcinoma; IL; interleukin; LRT; locoregional therapy; MN-16ET; N-[2-(triphenylmethyl)thioethyl]-3-aza-19-ethyloxycarbonyl-3-[2-(triphenylmethyl)thio
Keywords: ANOVA; analysis of variance; DEE; drug-eluting embolic; HCC; hepatocellular carcinoma; ICC; intrahepatic cholangiocarcinoma; mCRC; metastatic colorectal carcinoma; SHAPD; systemic-hepatic artery pressure difference; SIS; Surefire Infusion System; TARE; tr
Keywords: DEE; drug-eluting embolic; DSA; digital subtraction angiography; HCC; hepatocellular carcinoma; LIPA; left inferior phrenic artery; RIPA; right inferior phrenic artery;
Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens
Keywords: DEE; drug-eluting embolic; FTIR; Fourier transform infrared; HCC; hepatocellular carcinoma; LLOQ; lowest limit of quantification;
Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center
Keywords: BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; DEE; drug-eluting embolic; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; ORR; overall res
Transarterial Chemoembolization of Renal Cell Carcinoma: A Prospective Controlled Trial
Keywords: DEE; drug-eluting embolic; mRECIST; modified Response Evaluation Criteria In Solid Tumors; NSS; nephron-sparing surgery; RCC; renal cell carcinoma; RN; radical nephrectomy; TAE; transarterial embolization; VAS; visual analog scale;
Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis
Keywords: BCLC; Barcelona Clinic Liver Cancer; CR; complete response; DEE; drug-eluting embolic; ECOG; Eastern Cooperative Oncology Group; HCC; hepatocellular carcinoma; IDR; intrahepatic distant recurrence; LTP; local tumor progression; PFS; progression-free survi
Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy
Keywords: BCLC; Barcelona Clinic Liver Cancer; CLM; colorectal carcinoma liver metastases; CRC; colorectal carcinoma; DEBIRI; drug-eluting beads loaded with irinotecan; DEE; drug-eluting embolic; ECOG; Eastern Cooperative Oncology Group; GM-CSF; granulocyte-macroph
Safety and Efficacy of 70-150 μm and 100-300 μm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma
Keywords: BCLC; Barcelona Clinic Liver Cancer; DEB; drug-eluting bead; DEE; drug-eluting embolic; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors;
A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma
Keywords: AST; aspartate aminotransferase; BCLC; Barcelona Clinic Liver Cancer; DEE; drug-eluting embolic; HCC; hepatocellular carcinoma;
Idarubicin-Loaded ONCOZENE Drug-Eluting Embolic Agents for Chemoembolization of Hepatocellular Carcinoma: In Vitro Loading and Release and In Vivo Pharmacokinetics
Keywords: AE; adverse event; AUC0-24 h; area under the concentration-time curve from 0-24 hours; Cmax; maximum concentration; DEE; drug-eluting embolic; HCC; hepatocellular carcinoma; LLOQ; lower limit of quantification; MDR; multidrug resistance; PK; pharmacok